Your browser doesn't support javascript.
loading
Factors influencing adverse events following COVID-19 vaccination.
Villanueva, Paola; McDonald, Ellie; Croda, Julio; Croda, Mariana Garcia; Dalcolmo, Margareth; Dos Santos, Glauce; Jardim, Bruno; Lacerda, Marcus; Lynn, David J; Marshall, Helen; Oliveira, Roberto D; Rocha, Jorge; Sawka, Alice; Val, Fernando; Pittet, Laure F; Messina, Nicole L; Curtis, Nigel.
Afiliación
  • Villanueva P; Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia.
  • McDonald E; Infection, Immunity & Global Health, Murdoch Children's Research Institute, Parkville, VIC, Australia.
  • Croda J; Infectious Diseases, Royal Children's Hospital Melbourne, Parkville, VIC, Australia.
  • Croda MG; Department of General Medicine, Royal Children's Hospital Melbourne, Parkville, VIC, Australia.
  • Dalcolmo M; Infection, Immunity & Global Health, Murdoch Children's Research Institute, Parkville, VIC, Australia.
  • Dos Santos G; School of Medicine, Federal University of Mato Grosso do Sul, Campo Grande, MS, Brazil.
  • Jardim B; Fiocruz Mato Grosso do Sul, Fundação Oswaldo Cruz, Campo Grande, Mato Grosso do Sul, Brazil.
  • Lacerda M; Yale School of Public Health, New Haven, CT, USA.
  • Lynn DJ; School of Medicine, Federal University of Mato Grosso do Sul, Campo Grande, MS, Brazil.
  • Marshall H; Helio Fraga Reference Center, Oswaldo Cruz Foundation Ministry of Health, Rio de Janeiro, Brazil.
  • Oliveira RD; Pontifical Catholic University of Rio de Janeiro, Rio de Janeiro, Brazil.
  • Rocha J; Helio Fraga Reference Center, Oswaldo Cruz Foundation Ministry of Health, Rio de Janeiro, Brazil.
  • Sawka A; Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil.
  • Val F; Carlos Borborema Clinical Research Unit, Manaus, Brazil.
  • Pittet LF; Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil.
  • Messina NL; Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia.
  • Curtis N; Flinders Health and Medical Research Institute, Flinders University, Bedford Park, SA, Australia.
Hum Vaccin Immunother ; 20(1): 2323853, 2024 Dec 31.
Article en En | MEDLINE | ID: mdl-38445666
ABSTRACT
Various novel platform technologies have been used for the development of COVID-19 vaccines. In this nested cohort study among healthcare workers in Australia and Brazil who received three different COVID-19-specific vaccines, we (a) evaluated the incidence of adverse events following immunization (AEFI); (b) compared AEFI by vaccine type, dose and country; (c) identified factors influencing the incidence of AEFI; and (d) assessed the association between reactogenicity and vaccine anti-spike IgG antibody responses. Of 1302 participants who received homologous 2-dose regimens of ChAdOx1-S (Oxford-AstraZeneca), BNT162b2 (Pfizer-BioNTech) or CoronaVac (Sinovac), 1219 (94%) completed vaccine reaction questionnaires. Following the first vaccine dose, the incidence of any systemic reaction was higher in ChAdOx1-S recipients (374/806, 46%) compared with BNT162b2 (55/151, 36%; p = 0.02) or CoronaVac (26/262, 10%; p < 0.001) recipients. After the second vaccine dose, the incidence of any systemic reaction was higher in BNT162b2 recipients (66/151, 44%) compared with ChAdOx1-S (164/806, 20%; p < 0.001) or CoronaVac (23/262, 9%; p < 0.001) recipients. AEFI risk was higher in younger participants, females, participants in Australia, and varied by vaccine type and dose. Prior COVID-19 did not impact the risk of AEFI. Participants in Australia compared with Brazil reported a higher incidence of any local reaction (170/231, 74% vs 222/726, 31%, p < 0.001) and any systemic reaction (171/231, 74% vs 328/726, 45%, p < 0.001), regardless of vaccine type. Following a primary course of ChAdOx1-S or CoronaVac vaccination, participants who did not report AEFI seroconverted at a similar rate to those who reported local or systemic reactions. In conclusion, we found that the incidence of AEFI was influenced by participant age and COVID-19 vaccine type, and differed between participants in Australia and Brazil.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Límite: Female / Humans Idioma: En Revista: Hum Vaccin Immunother Año: 2024 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Límite: Female / Humans Idioma: En Revista: Hum Vaccin Immunother Año: 2024 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos